Advertisement

PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 31–31 | Cite as

Sarilumab therapy for rheumatoid arthritis achieves budget savings

Clinical study
  • 3 Downloads

Reference

  1. Ferrufino CP, et al. Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies. ClinicoEconomics and Outcomes Research 2018: 805-819, No. 10, 16 Nov 2018. Available from: URL: https://doi.org/10.2147/CEOR.S163829 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations